Biosimilars 2020 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
FEBRUARY 4, 2021
BI argues that FDA’s current interpretation “encourages, or at least permits, brand sponsors to use minor concentration changes as an anti-competitive tactic.” In particular, Judge Reyna would have interpreted the “2004 Accord & Satisfaction between Roche. . . BI points to Humira ® (adalimumab) as an example.
52 
Let's personalize your content